Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C.
Mochizuki K, Kagawa T, Takashimizu S, Kawazoe K, Kojima S, Nagata N, Nakano A, Nishizaki Y, Shiraishi K, Itakura M, Watanabe N, Mine T, Matsuzaki S. Mochizuki K, et al. Among authors: nagata n. World J Gastroenterol. 2004 Mar 1;10(5):733-6. doi: 10.3748/wjg.v10.i5.733. World J Gastroenterol. 2004. PMID: 14991949 Free PMC article. Clinical Trial.
Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C.
Numata M, Kagawa T, Kojima S, Hirose S, Nagata N, Shiraishi K, Watanabe N, Shiozawa H, Nishizaki Y, Motegi S, Takashimizu S, Kamochi J, Wasada M, Ohno T, Tei Y, Nakano A, Yamada T, Atsukawa K, Watanabe T, Mine T. Numata M, et al. Among authors: nagata n. Hepat Res Treat. 2010;2010:702748. doi: 10.1155/2010/702748. Epub 2010 Aug 23. Hepat Res Treat. 2010. PMID: 21188199 Free PMC article.
Weight-based high- and low-dose ribavirin in combination with peginterferon α-2b therapy for genotype 2 chronic hepatitis C: A randomized trial.
Kagawa T, Kojima S, Shiraishi K, Takashimizu S, Nagata N, Shiozawa H, Nishizaki Y, Ikeda A, Tei Y, Atsukawa K, Kamochi J, Wasada M, Numata M, Arase Y, Hirose S, Yamada T, Hata Y, Watanabe N, Morizane T, Mine T. Kagawa T, et al. Among authors: nagata n. Hepatol Res. 2012 Apr;42(4):351-8. doi: 10.1111/j.1872-034X.2011.00944.x. Epub 2011 Dec 16. Hepatol Res. 2012. PMID: 22176474
Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial.
Kagawa T, Kojima S, Shiraishi K, Hirose S, Arase Y, Takashimizu S, Watanabe N, Nagata N, Numata M, Shiozawa H, Nishizaki Y, Toki M, Sugita T, Nomura K, Sakaguchi T, Atsukawa K, Tajima H, Tei Y, Inomoto T, Mine T. Kagawa T, et al. Among authors: nagata n. Hepatol Res. 2013 Sep;43(9):925-32. doi: 10.1111/hepr.12046. Epub 2013 Jan 29. Hepatol Res. 2013. PMID: 23356876
Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon alpha-2a in the treatment of chronic hepatitis C.
Kagawa T, Shiozawa H, Kojima S, Takashimizu S, Nagata N, Numata M, Morino F, Nishizaki Y, Mochizuki K, Watanabe N, Watanabe T, Matsuzaki S, Mine T. Kagawa T, et al. Among authors: nagata n. Hepatol Res. 2008 Mar;38(3):259-66. doi: 10.1111/j.1872-034X.2007.00260.x. Epub 2007 Sep 6. Hepatol Res. 2008. PMID: 17825059
1,376 results